- Vaxart (VXRT, Financial) will disclose Phase I norovirus trial results on June 11, 2025.
- A conference call will be hosted at 8:30 AM ET to review and discuss these results.
- Investors can access the call online or via provided phone lines, with a replay available afterward.
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company focusing on developing oral recombinant pill vaccines, has announced the upcoming release of topline results from its Phase I norovirus trial. The data will be made available to the public on June 11, 2025, before the market opens.
The Vaxart senior management team will hold a live conference call on June 11, 2025, at 8:30 AM ET to discuss the trial results in detail and provide an update on the study's progress. Interested investors can join the webcast or use the domestic line (877) 407-0832 or international line (201) 689-8433 with the Conference ID 13754315 to participate in the call. Additionally, investors are encouraged to submit their questions in advance by emailing [email protected].
Vaxart is at the forefront of developing a range of oral vaccines, leveraging its proprietary delivery platform designed to administer vaccines in pill form. This innovative approach offers significant advantages, including ease of storage without refrigeration and eliminating the risk of needle-stick injuries. Current development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for HPV.
Following the conference call, a replay will be available on the company’s website at www.vaxart.com, allowing interested parties and stakeholders to revisit the session at their convenience.
